keyword
MENU ▼
Read by QxMD icon Read
search

Alemtuzumab

keyword
https://www.readbyqxmd.com/read/28101520/an-observational-study-of-alemtuzumab-following-fingolimod-for-multiple-sclerosis
#1
Mark Willis, Owen Pearson, Zsolt Illes, Tobias Sejbaek, Christian Nielsen, Martin Duddy, Kate Petheram, Caspar van Munster, Joep Killestein, Clas Malmeström, Emma Tallantyre, Neil Robertson
OBJECTIVE: To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab. METHODS: Patients with relapsing MS treated sequentially with fingolimod then alemtuzumab who experienced significant subsequent disease activity were identified by personal communication with 6 different European neuroscience centers. RESULTS: Nine patients were identified...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28090498/successful-treatment-of-steroid-refractory-immune-thrombocytopenia-with-alemtuzumab
#2
Chul Won Jung, Su-Hee Cho, Sylvia Park, Jun Ho Jang, Jun Ho Ji
No abstract text is available yet for this article.
December 2016: Blood Research
https://www.readbyqxmd.com/read/28089878/pre-transplant-absolute-lymphocyte-counts-impact-the-pharmacokinetics-of-alemtuzumab
#3
Rebecca Marsh, Tsuyoshi Fukuda, Chie Emoto, Lisa Neumeier, Pooja Khandelwal, Sharat Chandra, Ashley Teusink, Alexander Vinks, Parinda A Mehta
Alemtuzumab is frequently used as part of reduced intensity conditioning (RIC) regimens for the allogeneic hematopoietic cell transplantation (HCT) of pediatric patients with non-malignant diseases. We have previously suggested an optimal Day 0 targeted range of alemtuzumab, but there are no pediatric data regarding the pharmacokinetics (PK) of subcutaneous alemtuzumab to guide precision dosing trials. The goal of this study was to prospectively characterize alemtuzumab PK and to explore absolute lymphocyte count (ALC) as a predictor of interindividual variability...
January 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28073178/polyclonal-and-monoclonal-antibodies-for-induction-therapy-in-kidney-transplant-recipients
#4
REVIEW
Penny Hill, Nicholas B Cross, A Nicholas R Barnett, Suetonia C Palmer, Angela C Webster
BACKGROUND: Prolonging kidney transplant survival is an important clinical priority. Induction immunosuppression with antibody therapy is recommended at transplantation and non-depleting interleukin-2 receptor monoclonal antibodies (IL2Ra) are considered first line. It is suggested that recipients at high risk of rejection should receive lymphocyte-depleting antibodies but the relative benefits and harms of the available agents are uncertain. OBJECTIVES: We aimed to: evaluate the relative and absolute effects of different antibody preparations (except IL2Ra) when used as induction therapy in kidney transplant recipients; determine how the benefits and adverse events vary for each antibody preparation; determine how the benefits and harms vary for different formulations of antibody preparation; and determine whether the benefits and harms vary in specific subgroups of recipients (e...
January 11, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28032335/eradication-of-minimal-residual-disease-improves-overall-and-progression-free-survival-in-patients-with-chronic-lymphocytic-leukaemia-evidence-from-ncrn-cll207-a-phase-ii-trial-assessing-alemtuzumab-consolidation
#5
Abraham M Varghese, Dena R Howard, Christopher Pocock, Andy C Rawstron, George Follows, Helen McCarthy, Claire Dearden, Christopher Fegan, Donald Milligan, Alexandra F Smith, Walter Gregory, Peter Hillmen
With immunochemotherapy, remission duration and survival in patients with chronic lymphocytic leukaemia is dependent on the level of minimal residual disease (MRD) after treatment. This phase II trial assessed alemtuzumab consolidation post-chemotherapy in patients who responded with persistent low levels of detectable disease. Blood was screened for MRD using multi-parameter flow cytometry, 6-24 months post-chemotherapy. MRD-positive participants received alemtuzumab 30 mg subcutaneously 3 times weekly for 6 weeks...
December 29, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/28029020/clinical-update-in-aspects-of-the-management-of-autoimmune-thyroid-diseases
#6
REVIEW
Duncan J Topliss
Aspects of autoimmune thyroid disease updated in this review include: immunoglobulin G4 (IgG4)-related thyroid disease (Riedel's thyroiditis, fibrosing variant of Hashimoto's thyroiditis, IgG4-related Hashimoto's thyroiditis, and Graves' disease with elevated IgG4 levels); recent epidemiological studies from China and Denmark indicating that excess iodine increases the incidence of Hashimoto's thyroiditis and hypothyroidism; immunomodulatory agents (ipilimumab, pembrolizumab, nivolumab) activate immune response by inhibiting T-cell surface receptors which down-regulate immune response, i...
December 2016: Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28008661/rescue-alemtuzumab-for-refractory-acute-cellular-rejection-and-bronchiolitis-obliterans-syndrome-after-lung-transplantation
#7
Christopher R Ensor, Lindsey C Rihtarchik, Matthew R Morrell, J W Awori Hayanga, Alicia B Lichvar, Joseph M Pilewski, Stephen Wisniewski, Bruce A Johnson, Jonathan D'Cunha, Adriana Zeevi, John F McDyer
Refractory acute-cellular rejection (rACR) is associated with death and bronchiolitis obliterans syndrome (BOS) post-lung transplantation. We report the largest cohort of lung transplant recipients (LTR) treated with rescue alemtuzumab for rACR or BOS. RACR outcomes included burden of ACR 30-days before and 180-days after rescue assessed by a novel composite rejection standardized score (CRSS, range 0-6); freedom from ≥A2 ACR. BOS outcomes included freedom from BOS progression and FEV1 decline >10%. Univariate parametric and nonparametric statistical approaches were used to assess treatment response...
December 23, 2016: Clinical Transplantation
https://www.readbyqxmd.com/read/27993172/immune-reconstitution-20%C3%A2-years-after-treatment-with-alemtuzumab-in-a-rheumatoid-arthritis-cohort-implications-for-lymphocyte-depleting-therapies
#8
Faye A H Cooles, Amy E Anderson, Tracey Drayton, Rachel A Harry, Julie Diboll, Lee Munro, Nishanthi Thalayasingham, Andrew J K Östör, John D Isaacs
BACKGROUND: Alemtuzumab, an anti-CD52 monoclonal antibody, was administered to patients with RA between 1991 and 1994. We have followed a cohort of recipients since that time and previously reported significant delays in immune reconstitution. Here we report >20 years of follow-up data from this unique cohort. METHOD: Surviving alemtuzumab recipients were age, sex and disease duration matched with RA controls. Updated mortality and morbidity data were collected for alemtuzumab recipients...
December 20, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27970881/cost-utility-analysis-of-alemtuzumab-versus-natalizumab-for-the-treatment-of-relapsing-remitting-multiple-sclerosis-us-payer-perspective
#9
A Smith, L Hashemi, I Ma
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970863/alemtuzumab-budget-impact-for-multiple-sclerosis-treatment-in-spain
#10
M Casellas, M Rubio
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27964705/biological-drugs-in-guillain-barr%C3%A3-syndrome-an-update
#11
Nazgol Motamed-Gorji, Nassim Matin, Omidreza Tabatabaie, Piero Pavone, Catia Romano, Raffaele Falsaperla, Giovanna Vitaliti
BACKGROUND: Guillain-Barré Syndrome (GBS) is currently considered the most common global cause of acute flaccid paralysis. Currently, standard therapy for Guillain-Barré Syndrome includes intravenous immunoglobulin or plasma exchange. Despite medical advances regarding these treatments many patients treated with them do not reach full recovery. Therefore, during last decades several biological agents have attracted the attentions from researchers and various studies have investigated their role in Guillain-Barré Syndrome...
December 13, 2016: Current Neuropharmacology
https://www.readbyqxmd.com/read/27941776/low-dose-alemtuzumab-for-gvhd-prevention-followed-by-prophylactic-donor-lymphocyte-infusions-in-high-risk-leukemia
#12
P Tsirigotis, M Liga, K Gkirkas, M Stamouli, E Triantafyllou, M Marangos, I Pessach, A Sarantopoulos, N Spyridis, A Spyridonidis
We analyzed the use of low-dose alemtuzumab in a cohort of 158 consecutive patients who underwent allogeneic PBSC transplantation. Patients with high-risk acute leukemia were prospectively screened for prophylactic donor lymphocyte infusion (pDLI). Lymphocytes were administered repeatedly at low and non-escalating doses (0.5-1 × 10(6)/kg). Low-dose alemtuzumab was effective in prevention of acute GvHD after sibling or well-matched unrelated transplantation, whereas a more intensified approach was needed after mismatched transplantation...
December 12, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27925187/depletion-of-cd52-positive-cells-inhibits-the-development-of-central-nervous-system-autoimmune-disease-but-deletes-an-immune-tolerance-promoting-cd8-t-cell-population-implications-for-secondary-autoimmunity-of-alemtuzumab-in-multiple-sclerosis
#13
Stephanie von Kutzleben, Gareth Pryce, Gavin Giovannoni, David Baker
The objective was to determine whether CD52 lymphocyte depletion can act to promote immunological tolerance induction by way of intravenous antigen administration such that it could be used to either improve efficiency of multiple sclerosis (MS) inhibition or inhibit secondary autoimmunities that may occur following alemtuzumab use in MS. Relapsing experimental autoimmune encephalomyelitis was induced in ABH mice and immune cell depletion was therapeutically applied using mouse CD52 or CD4 (in conjunction with CD8 or CD20) depleting monoclonal antibodies...
December 7, 2016: Immunology
https://www.readbyqxmd.com/read/27918372/the-first-90-days-temporary-effect-of-alemtuzumab-on-cmv-immune-reconstitution
#14
Davide Abate
No abstract text is available yet for this article.
December 1, 2016: Transplantation
https://www.readbyqxmd.com/read/27915429/high-risk-pml-patients-switching-from-natalizumab-to-alemtuzumab-an-observational-study
#15
Simona Malucchi, Marco Capobianco, Marianna Lo Re, Maria Malentacchi, Alessia di Sapio, Manuela Matta, Francesca Sperli, Antonio Bertolotto
INTRODUCTION: The choice of therapy in patients withdrawing from natalizumab treatment is still an open question and neurologists need strategies to manage this group of patients. The aim of this study is to evaluate if alemtuzumab is able to control the disease when used in patient who have stopped natalizumab. METHODS: 16 patients stopped natalizumab treatment after a median number of 20 infusions (range 12-114); all the patients were responders to natalizumab (neither clinical nor radiological activity during natalizumab therapy) and the reason for stopping was the risk of PML for all of them...
December 3, 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27891572/safety-concerns-and-risk-management-of-multiple-sclerosis-therapies
#16
REVIEW
P Soelberg Sorensen
Currently, more than ten drugs have been approved for treatment of relapsing-remitting multiple sclerosis (MS). Newer treatments may be more effective, but have less favorable safety record. Interferon-β preparations and glatiramer acetate treatment require frequent subcutaneous or intramuscular injections and are only moderately effective, but have very rarely life-threatening adverse effects, whereas teriflunomide and dimethyl fumarate are administered orally and have equal or better efficacy, but have more potentially severe adverse effects...
November 27, 2016: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/27888093/randomized-trial-of-ratg-daclizumab-vs-ratg-alemtuzumab-as-dual-induction-therapy-in-renal-transplantation-results-at-8years-of-follow-up
#17
Gaetano Ciancio, Jeffrey J Gaynor, Giselle Guerra, Junichiro Sageshima, David Roth, Linda Chen, Warren Kupin, Adela Mattiazzi, Lissett Tueros, Sandra Flores, Lois Hanson, Phillip Ruiz, Rodrigo Vianna, George W Burke
Our goal in using dual induction therapy is to bring the kidney transplant recipient closer (through more effectively timed lymphodepletion) to an optimally immunosuppressed state. Here, we report long-term results of a prospective randomized trial comparing (Group I,N=100) rATG/Dac (3 rATG, 2 Dac doses) vs. (Group II,N=100) rATG/Alemtuzumab(C1H) (1 dose each), using reduced tacrolimus dosing, EC-MPS, and early corticosteroid withdrawal. Lower EC-MPS dosing was targeted in Group II to avoid severe leukopenia...
November 22, 2016: Transplant Immunology
https://www.readbyqxmd.com/read/27885061/alemtuzumab-improves-quality-of-life-outcomes-compared-with-subcutaneous-interferon-beta-1a-in-patients-with-active-relapsing-remitting-multiple-sclerosis
#18
Rafael Arroyo González, Mariko Kita, Heidi Crayton, Eva Havrdova, David H Margolin, Stephen L Lake, Gavin Giovannoni
BACKGROUND: Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis. OBJECTIVE: To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials. METHODS: Patients who were treatment naive (Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 µg three times/week...
November 1, 2016: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/27882532/alemtuzumab-use-in-clinical-practice-recommendations-from-european-multiple-sclerosis-experts
#19
Thomas Berger, Irina Elovaara, Sten Fredrikson, Chris McGuigan, Lucia Moiola, Kjell-Morten Myhr, Celia Oreja-Guevara, Igor Stoliarov, Uwe K Zettl
Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in the USA, the indication states that alemtuzumab should generally be reserved for the treatment of patients with relapsing forms of multiple sclerosis who have had an inadequate response to two or more disease-modifying therapies (DMTs)...
November 23, 2016: CNS Drugs
https://www.readbyqxmd.com/read/27862703/alemtuzumab-campath-1h-therapy-for-refractory-rejections-in-pediatric-heart-transplant-recipients
#20
Bibhuti Das, Vivian Dimas, Kristine Guleserian, Chantale Lacelle, Kristin Anton, Lindy Moore, Robert Morrow
Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22%±5% to 33%±5% (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection...
November 11, 2016: Pediatric Transplantation
keyword
keyword
41276
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"